Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.8% – Here’s What Happened

Vera Therapeutics, Inc. (NASDAQ:VERA) shares were down 5.8% during mid-day trading on Tuesday . The stock traded as low as $29.67 and last traded at $30.3690. 498,425 shares changed hands during trading, a decline of 64% from the average daily volume of 1,387,335 shares. The stock had previously closed at $32.23.

Analysts Set New Price Targets

VERA has been the subject of a number of recent analyst reports. Evercore set a $91.00 target price on Vera Therapeutics in a report on Friday, May 15th. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Wedbush boosted their price objective on shares of Vera Therapeutics from $35.00 to $43.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, HC Wainwright raised their target price on shares of Vera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.58.

Vera Therapeutics Stock Down 4.2%

The company has a market capitalization of $2.22 billion, a P/E ratio of -5.60 and a beta of 0.92. The company has a 50-day moving average of $36.87 and a two-hundred day moving average of $39.46. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period last year, the company posted ($0.81) earnings per share. On average, research analysts predict that Vera Therapeutics, Inc. will post -6.37 EPS for the current year.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares in the company, valued at $6,429,346.20. This trade represents a 23.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 83,250 shares of company stock valued at $3,337,770. 15.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at approximately $46,000. Quantbot Technologies LP purchased a new stake in shares of Vera Therapeutics in the 2nd quarter worth approximately $51,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Vera Therapeutics in the 4th quarter worth approximately $71,000. Tower Research Capital LLC TRC increased its position in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after buying an additional 2,757 shares in the last quarter. Finally, Sandia Investment Management LP bought a new position in Vera Therapeutics during the 4th quarter valued at approximately $127,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.